Company Profile

Curefaktor Pharmaceuticals LLC
Profile last edited on: 1/31/16      CAGE: 5WR01      UEI:

Business Identifier: Focal Adhesion Kinase treatments for cancer.
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

14 Rockdove Lane
Orchard Park, NY 14127
   (716) 525-3985
Location: Single
Congr. District: 27
County: Erie

Public Profile

CureFAKtor Pharmaceuticals is a biotechnology focused on developing treatments for cancer based on research involving the role of the Focal Adhesion Kinase (FAK) protein. FAK is over-expressed in tumors and plays a role in facilitating the growth and spread of tumors, as well as tumor resistance to chemotherapeutic drugs and radiation. The company's products target FAK to treat pancreatic, breast, colon, melanoma, lung and brain oncology disorders. CureFAKtor is planning a Phase I clinical study of its CFAK-C4 treatment in combination with gemcitabine chemotherapy for pancreatic cancer.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2014 1 NIH $219,534
Project Title: Novel Focal Adhesion Kinase Autophosphorylation Inhibitors Against Pancreatic Cancer

Key People / Management

  H Shep Wild -- President and CEO

  Vita M Golubovskaya

  Thomas Mathers -- Former Director